Our discovery that PRMT1-catalyzed METTL14 arginine methylation plays a critical role in promoting ICL DNA repair gene expression reveals a new way of sensitizing cancer cells to ICL chemotherapy through targeting the METTL14 arginine methylation mediated m6A pathway. This evidence concerns the gene METTL14 and cancer.